US equities
|
SPCX
$167.13
▲+5.14%
NVDA
$236.27
▲+0.99%
MU
$1,064.54
▼-0.96%
TSLA
$378.60
▲+2.16%
MSFT
$525.07
▲+1.46%
SNDK
$1,709.31
▼-0.62%
INTC
$117.36
▼-1.65%
META
$743.77
▲+2.16%
SPCX
$167.13
▲+5.14%
NVDA
$236.27
▲+0.99%
MU
$1,064.54
▼-0.96%
TSLA
$378.60
▲+2.16%
MSFT
$525.07
▲+1.46%
SNDK
$1,709.31
▼-0.62%
INTC
$117.36
▼-1.65%
META
$743.77
▲+2.16%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Optimi Health Corp
(CSE:
OPTI
)
6.120
-0.280 (-4.38%)
Delayed Quote
Updated: 12:15 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Optimi Health Corp
BioMedNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 3 MDMA-Assisted Therapy Trial for PTSD
September 16, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 2 Psilocybin Trial for Major Depressive Disorder
September 10, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes First Psilocybin Export to United Kingdom for Planned Phase 2 Trial
June 10, 2026
Via
Investor Brand Network
Topics
Supply Chain
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
June 10, 2026
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from...
From
OPTIMI HEALTH CORP.
Via
GlobeNewswire
BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Advances Ibogaine Drug Development Program
June 08, 2026
Via
Investor Brand Network
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
June 08, 2026
From
OPTIMI HEALTH CORP.
Via
GlobeNewswire
BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes GMP Production Run of 5mg Psilocybin Drug Product
June 02, 2026
Via
Investor Brand Network
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
June 02, 2026
From
OPTIMI HEALTH CORP.
Via
GlobeNewswire
NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update
May 29, 2026
Via
Investor Brand Network
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
May 29, 2026
From
OPTIMI HEALTH CORP.
Via
GlobeNewswire
PsychedelicNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity
May 27, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Prices $15 Million Public Offering in Connection With Nasdaq Uplisting
May 21, 2026
Via
Investor Brand Network
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
May 20, 2026
(May 20, 2026) - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and
Via
PressReach
Topics
Regulatory Compliance
PsychedelicNewsBreaks – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) Launches Ibogaine Initiative Amid U.S. Policy Shift
April 21, 2026
Via
Investor Brand Network
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
April 20, 2026
(April 20, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic
Via
PressReach
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
March 16, 2026
Vancouver, British Columbia-March 16, 2026 - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE:8BN) (the "Company" or "Optimi"), a commercial-stage
Via
PressReach
Topics
Regulatory Compliance
Optimi Health Completes MD-MA Export for PTSD Treatment Under Australia’s Authorised Prescriber Scheme
February 09, 2026
(February 9, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychoactive
Via
PressReach
Optimi Health Completes First 2026 Production of MD-MA and Psilo Capsules
January 26, 2026
(January 26, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug
Via
PressReach
Early Warning Press Release in Accordance with National Instrument 62-103
April 04, 2024
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 110,000 common shares (each...
Via
Newsfile
Optimi Health Announces C$3.27 Million Private Placement with Strategic Investment from Lululemon Founder Chip Wilson
October 12, 2022
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP-grade psilocybin, synthetic psychedelic substances and...
Via
PressReach
Psychedelic Drugs Prove Their Worth In Clinical Trials
October 11, 2022
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial...
Via
PressReach
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll...
Via
PressReach
Topics
Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...
Via
FinancialNewsMedia
Topics
Cannabis
Optimi Health and ATMA Journey Centers to Send a Clinical Trial Application to Health Canada for Phase I Natural Psilocybin and MDMA
September 22, 2022
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian company that makes natural, scalable, and easy-to-get psychedelic and functional mushrooms, as well as synthetic formulations, to help people...
Via
PressReach
Topics
Supply Chain
Psychedelics May Make People Less Afraid of Death
September 07, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change...
Via
FinancialNewsMedia
Topics
Supply Chain
Psychedelics Use Among Young Adults Reaches All-Time High
September 01, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health survey,...
Via
FinancialNewsMedia
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
August 10, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study...
Via
FinancialNewsMedia
Topics
Supply Chain
Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application
October 05, 2021
Company utilizes green chemistry to stabilize natural product with higher yields Vancouver, BC – October 5, 2021 – Optimi Health Corp. (OTCQB: OPTHF) (CSE: OPTI) (FRA: 8BN) (“Optimi” or the “Company”),...
Via
FinancialNewsMedia
Topics
Intellectual Property
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
July 07, 2021
Via
FinancialNewsMedia
Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
October 05, 2021
Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to...
Via
FinancialNewsMedia
